SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Oxygenta Pharma - Quaterly Results

30 May 2025 Evaluate
The total revenue hovered 368.79% to Rs. 494.67 millions for the March 2025 quarter as against Rs. 105.52 millions during the corresponding quarter last year.The Net Loss for the quarter ended March 2025 is Rs. -21.52 millions as compared to Net Profit of Rs. 80.15 millions of corresponding quarter ended March 2024 Operating profit Margin for the quarter ended March 2025 further decreased to -16.34% as compared to -16.02% of corresponding quarter ended March 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 494.67 105.52 368.79 1092.99 396.42 175.72 1092.99 396.42 175.72
Other Income 0.49 0.13 276.92 13.09 0.42 3016.67 13.09 0.42 3016.67
PBIDT -16.34 -16.02 2.00 -86.84 -96.54 -10.05 -86.84 -96.54 -10.05
Interest 21.28 5.95 257.65 36.14 26.61 35.81 36.14 26.61 35.81
PBDT -40.32 -19.50 106.77 -125.68 -122.78 2.36 -125.68 -122.78 2.36
Depreciation -2.34 6.38 -136.68 17.82 15.94 11.79 17.82 15.94 11.79
PBT -37.98 -25.88 46.75 -143.50 -138.72 3.45 -143.50 -138.72 3.45
TAX -16.46 -106.03 -84.48 -40.53 -103.92 -61.00 -40.53 -103.92 -61.00
Deferred Tax -18.06 -106.03 -82.97 -42.13 -103.92 -59.46 -42.13 -103.92 -59.46
PAT -21.52 80.15 -126.85 -102.97 -34.80 195.89 -102.97 -34.80 195.89
Equity 369.84 334.84 10.45 369.84 334.84 10.45 369.84 334.84 10.45
PBIDTM(%) -3.30 -15.18 -78.24 -7.95 -24.35 -67.37 -7.95 -24.35 -67.37

Oxygenta Pharma Share Price

57.67 1.61 (2.87%)
11-May-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1282.15
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2249.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×